Our findings also raise the debate whether all DLBCL should be investigated for MYC translocation with regard to risk stratification in routine histopathological diagnosis by interphase FISH or first screened by MYC immunohistochemistry (where necessary immunohistochemistry with an alternative antibody to rule out potential false negative due to mutation impairing the antibody binding site [12]), and only cases with MYC protein expression above a certain level (to be determined) selected for further FISH analyses. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.